ACADIA Pharmaceuticals Inc. (ACAD) announced positive results from its Phase III trial of pimavanserin, in patients with Parkinson's disease psychosis. Pimavanserin met the primary endpoint by demonstrating highly significant antipsychotic efficacy as measured using the 9-item SAPS-PD scale. The drug also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson's Disease Rating Scale.
ACADIA Pharmaceuticals gapped open dramatically higher Tuesday, but traded in a narrow range throughout the session. The stock closed up by 3.13 at $5.43 on the highest volume of the year and set a new 52-week high.
by RTT Staff Writer
For comments and feedback: email@example.com